

♦ GLKVs16 (iPS cells expressing the second highest HLA in Japan※1)

Clone ID	GLKVs16	Product	Human iPS cells
Source	Cord blood, Human	Race	Japanese
Passage No.	7	Gender	Male
Lot No.	20171003-20	Manufacture Dates	Oct. 3 rd , 2017
Culture medium	StemFit AK03N	Substrate	iMatrix-511MG
Culture Method	Feeder-free (**2)		
Plasmids for	pCE-hSK, pCE-hUL, pCE-hOCT3/4, pCE-mp53DD, pCXB-EBNA1		
reprograming			
Use and Provision	Please check our web site ;		
of this cell stock	https://www.cira-foundation.or.jp/e/project/stock.html		

^(※1) **Reference**; Okita, et. al., Nat Methods. 2011 8(5): 409-412

Test Result

Test	Method	Result
Sterility	BacT/ALERT	Negative
Mycoplasma	PCR	Negative
Endotoxin	LAL	≦ 5 EU/mL
Virus (HBV, HCV, HIV, HTLV, Parvovirus B19)	PCR	Negative
HLA typing (HLA-A, B, DR)	PCR-SBT	Consistent with the donor cells
STR genotyping	PCR	Consistent with the donor cells
Morphology	Microscope	Consistent with human ES cells
Karyotype	Conventional Giemsa analysis G-banding	46,XY[20]
Plasmid remnants	qPCR	Below the limit of quantification
CNV ^(*3)	WGS, SNP	No de novo CNVs (>1kbp) were found in COSMIC Cancer Gene Census (ver.85) and Shibata list ^(**5) .
SNV/Indel ^(※4)	WGS, WES	No de novo non-synonymous SNVs/Indels were found in COSMIC Cancer Gene Census (ver.85) and Shibata list ^(**5) .
Undifferentiated	Microarray ^(※7)	POU5F1 : 3.9%, NANOG : 12.3% (Relative expression levels of GAPDH)
markers	Flow cytometry (**7)	TRA-1-60: 97.8% SSEA4: 99.5% TRA-2-49: 99.4%


^(%2) **Reference**; Nakagawa, et. al., Nat Biotechnol. 2008 26(1):101-106



	Counting the number of the	
Thawed postnatal cells	cells with a disposable	2.14 × 10 ⁵ cells (Survival rate; 74.4%)
	hemocytometer (**6,7)	
	Counting the number of the	
Number of proliferating	cells with a disposable	8.3×10^5 cells (Number of seeded cells : 2.05
cells after thawing	hemocytometer after	× 10 ⁵ cells)
	culturing for 6 days(**6,7).	
	Counting the number of the cells (**6,7)	P10→P11: 26.8
		P11→P12: 34.6
Doubling time (h)		P12→P13: 32.5
		P13→P14: 29.9
		P14→P15: 27.6

- (%3) CNV; Copy Number Variation
- (¾4) SNV/Indel; Single nucleotide variants /Insertion Deletion
- (%5) The PMDA Science Board "Current Perspective on Evaluation of Tumorigenicity of Cellular- and Tissue-based Products Derived from induced Pluripotent Stem Cells (iPSCs) and iPSCs as Their Starting Materials" (Cellular- and Tissue-based Products Subcommittee, 20 August 2013)
- (%6) OLYMPUS Cell Counter model R1
- (※7) The result of # 1 out of 3 frozen stocks is shown.

■Image



Please contact us if you have any questions.

(ips-request@cira-foundation.or.jp)



